These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 29175009

  • 21. The advantage of Sirolimus in amplifying regulatory B cells and regulatory T cells in liver transplant patients.
    Song J, Du G, Chen W, Bao P, Li B, Lu Q, Shi B.
    Eur J Pharmacol; 2020 Feb 15; 869():172872. PubMed ID: 31846626
    [Abstract] [Full Text] [Related]

  • 22. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A, Tordera D, de la Sen ML, Jiménez L, Mas P, Muñoz C, Olivares J.
    Nefrologia; 2012 Feb 15; 32(5):631-8. PubMed ID: 23013949
    [Abstract] [Full Text] [Related]

  • 23. Combined therapy of CD4(+)CD25(+) regulatory T cells with low-dose sirolimus, but not calcineurin inhibitors, preserves suppressive function of regulatory T cells and prolongs allograft survival in mice.
    Ma A, Qi S, Wang Z, Massicotte E, Dupuis M, Daloze P, Chen H.
    Int Immunopharmacol; 2009 May 15; 9(5):553-63. PubMed ID: 19539558
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Influence of immunosuppressive drugs on the development of CD4(+)CD25(high) Foxp3(+) T cells in liver transplant recipients.
    Chu Z, Zhang J, Zhao Y, Ji Q, Zhong J, Zhang C, Zhang B.
    Transplant Proc; 2010 Sep 15; 42(7):2599-601. PubMed ID: 20832552
    [Abstract] [Full Text] [Related]

  • 29. mTOR Signaling Regulates Protective Activity of Transferred CD4+Foxp3+ T Cells in Repair of Acute Kidney Injury.
    Chen G, Dong Z, Liu H, Liu Y, Duan S, Liu Y, Liu F, Chen H.
    J Immunol; 2016 Nov 15; 197(10):3917-3926. PubMed ID: 27798166
    [Abstract] [Full Text] [Related]

  • 30. Effects of Conversion From Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients.
    Tsai KF, Li LC, Hsu CN, Lin CC, Lin YH, Cheng YF, Wang CC, Chen CL.
    J Clin Pharmacol; 2019 Mar 15; 59(3):326-334. PubMed ID: 30387865
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Safety of mTOR inhibitors in adult solid organ transplantation.
    Ventura-Aguiar P, Campistol JM, Diekmann F.
    Expert Opin Drug Saf; 2016 Mar 15; 15(3):303-19. PubMed ID: 26667069
    [Abstract] [Full Text] [Related]

  • 34. Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells.
    Shan J, Feng L, Sun G, Chen P, Zhou Y, Xia M, Li H, Li Y.
    Immunobiology; 2015 Apr 15; 220(4):510-7. PubMed ID: 25468562
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects.
    Granata S, Dalla Gassa A, Carraro A, Brunelli M, Stallone G, Lupo A, Zaza G.
    Int J Mol Sci; 2016 May 14; 17(5):. PubMed ID: 27187382
    [Abstract] [Full Text] [Related]

  • 38. mTOR inhibitors in pediatric liver transplant recipients.
    Dumortier J, Couchonnal E, Lacaille F, Rivet C, Debray D, Boillot O, Lachaux A, Ackermann O, Gonzales E, Wildhaber BE, Jacquemin E, McLin V.
    Clin Res Hepatol Gastroenterol; 2019 Aug 14; 43(4):403-409. PubMed ID: 30528864
    [Abstract] [Full Text] [Related]

  • 39. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
    Tedesco Silva H.
    Transplantation; 2018 Feb 14; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
    [No Abstract] [Full Text] [Related]

  • 40. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A, Diekmann F, Revuelta I, Esforzado N, Ricart MJ, Cofán F, Torregrosa JV, Peri L, Ruiz Á, Campistol JM, Oppenheimer F.
    Transpl Int; 2016 Mar 14; 29(3):362-8. PubMed ID: 26678359
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.